Surrozen raised $33m to fund drug development programs targeting Wnt ligands for various indications during a February VC financing flurry that occurred despite a drop in IPOs. Taking an alternative route to going public, some biopharma companies have completed reverse mergers in recent weeks and months.
February was a busy month for significant venture capital financings, with $483m raised by 15 biopharmaceutical companies, including a $33m Series A round for start-up Surrozen Inc., which is developing drugs targeting Wnt ligands to promote the repair and regeneration of human tissues.
The Surrozen financing was in line with the February average of $32.2m per deal, according to Scrip's tally of VC...
All eyes on chronic urticaria after eosinophilic esophagitis disappointment.
Glenmark signals thrust on high margin products, while exiting tail end brands as part of efforts to emerge as a branded company. In-licensed assets like Brukinsa and Tevimbra are seen as pivotal to driving growth alongside.
The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.
